Format

Send to

Choose Destination
Curr Opin Hematol. 2015 May;22(3):227-33. doi: 10.1097/MOH.0000000000000136.

Update of hematopoietic cell transplantation for sickle cell disease.

Author information

1
Jordan Family Director, Blood and Marrow Transplant Program, Division of Hematology/Oncology/BMT, UCSF Benioff Children's Hospital, Oakland, California, USA.

Abstract

PURPOSE OF REVIEW:

Hematopoietic cell transplantation (HCT) is a curative therapy for sickle cell disease (SCD) that is utilized very rarely because of limited allogeneic donor availability, limited healthcare resources needed to expand the treatment to regions in the world where most affected individuals reside, and by a view among SCD experts that HCT lacks the evidential rigor with short and long-term toxicity profiles that together might support its broader application.

RECENT FINDINGS:

In this update, recent advances focused on donor selection, reduced toxicity preparation for HCT, and treatment of young adults will be presented. The current status of conventional bone marrow transplantation with a human leukocyte antigen-identical sibling donor is summarized.

SUMMARY:

HCT for SCD is curative in almost all children who have a human leukocyte antigen-matched sibling donor. The future of this therapy will hinge on expanding the number of individuals who might be treated.

PMID:
25767957
PMCID:
PMC5037959
DOI:
10.1097/MOH.0000000000000136
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The author is a Medical Director of the ViaCord Processing Laboratory – a family umbilical cord blood banking facility – and has received honoraria from Biogen IDEC and Bluebird Bio, Inc., for advisory work in the past 12 months.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center